<DOC>
	<DOCNO>NCT00299884</DOCNO>
	<brief_summary>The primary aim study evaluate efficacy non-inferiority lipid-lowering medication regimen comprise medication ezetimibe fenofibrate take daily , versus atorvastatin daily lowering level low-density lipoprotein ( LDL-C ) cholesterol . Additionally , aim would include effect types blood cholesterol examine safety ezetimibe fenofibrate regimen , compare atorvastatin .</brief_summary>
	<brief_title>Atorvastatin Versus Ezetimibe Fenofibrate Lipid-lowering Strategy</brief_title>
	<detailed_description>It demonstrate several previous primary secondary study lower low-density lipoprotein cholesterol ( LDL-C ) use medication 3-hydroxy-3-methylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor improve mortality morbidity relate cardiovascular event patient hypercholesterolemia . Such inhibitor , know 'statins ' , act block synthesis cholesterol liver . These medication generally well tolerate vast majority patient , small number experience side effect , seriously myopathy , rhabdomyolysis elevate liver enzymes - recognition fact , statins universally without problem , highlight need viable alternative . Ezetimibe relatively new medication Canada , approve use patient cholesterol problem . It intestinal cholesterol binder know well-tolerated , side effect similar placebo . Alone , modest effect lower LDL-C. Fenofibrate medication also work liver long used adjust blood lipid level patient mixed lipid problem . Alone also modest effect lower LDL-C . Recent study , however , show effect ezetimibe fenofibrate together lower LDL-C great either drug alone . This combination , effective regard atorvastatin , would prove valid alternative use atorvastatin lower LDL-C , benefit patient problem tolerate statin therapy still require medication elevate cholesterol .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Study confine subject elevate LDLC level 3.0 mmol/L great . Abnormal liver enzyme ( ie , AST , ALT great three time upper limit normal ) ; Creatine kinase level two time upper limit normal ; Uncontrolled ethanol use ( may affect compliance ) ; Pregnant breastfeed woman woman use adequate contraceptive method ; Previous history intolerance adverse effect statin ; Previous history intolerance adverse effect fibric acid derivative ; Previous history intolerance adverse effect ezetimibe ; Uncontrolled diabetes ( HbA1c &gt; 10 % ) ; Recent myocardial infarction ( within 6 week ) ; Concurrent enrollment another study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Randomized</keyword>
	<keyword>non-blinded</keyword>
	<keyword>prospective</keyword>
	<keyword>open-label</keyword>
	<keyword>LDL-C</keyword>
	<keyword>HDL-C</keyword>
</DOC>